| 510(k) | Premarket Notification to the FDA, under Section 510(k) of the Food, Drug and Cosmetic Act, of intent to market a medical device in the USA |
| AGM | Annual General Meeting |
| ANZ | Australia and New Zealand |
| APES | Standards issued by the Accounting Professional & Ethical Standards Board (APESB) |
| ASUM | Australian Society for Ultrasound in Medicine |
| ASX | Australian Securities Exchange Limited |
| CDC | Centre for Disease Control (USA) |
| Clostridium difficile | A bacterium, the most common cause of infectious diarrhea in hospitals and long-term care homes |
| CMDCAS | Canadian Medical Devices Conformity Assessment System |
| DESP | Deferred Employee Share Plan |
| EESP | Exempt Employee Share Plan |
| EN15883 | A Standard, also known as HTM2030, for the testing of Washer Disinfectors for surgical instruments, including endoscopes, to ensure they are operating correctly. |
| EPS | Earnings Per Share |
| ESOP | Employee Share Option Plan |
| FDA | Food and Drug Administration – USA |
| Financial Year | Year to 30 June |
| Fiscal Year | Year to 30 June |
| FY | Financial year, eg. FY2011 is the financial year ending 30 June 2011 |
| Glutaraldehyde | Used to disinfect medical and dental equipment. It is toxic and can cause severe eye, nose, throat and lung irritation, along with headaches, drowsiness and dizziness. It is a main source of occupational asthma among health care providers (source Canadian Centre for Occupational Health and Safety- February 2005) . |
| Golden Staph | Staphylococcus aureus, or S. aureus - a common bacterium that can cause a range of mild to severe infections, even death. Some strains are resistant to antibiotics. |
| Group | Nanosonics Limited and its wholly owned subsidiary companies |
| GSOP | General Share Option Plan |
| GST | Goods and Services Tax |
| HIA | Healthcare Acquired Infection |
| HLD | High Level Disinfection - the minimum treatment recommended for reprocessing a device or item of equipment for use in a semi critical site, if it cannot be sterilised. It involves killing all microorganisms, with the exception of high numbers of bacterial spores. |
| HLD+ | High Level Disinfection Plus, including sporicidal efficacy - Nanosonics new dimension of disinfection based on the Company’s platform technologies |
| IASB | International Accounting Standards Board |
| IFRS | International Financial Reporting Standards |
| IP | Intellectual Property |
| ISO 13485 | Quality Management System for Medical Devices – Requirements for Regulatory Purposes |
| IVF | In-vitro fertilisation |
| KMP | Key Management Personnel (excludes non-Executive Directors) |
| LTI | Long Term Incentive |
| MRSA | Methicillin resistant staphylococcus aureus, a bacterium resistant to broad-spectrum antibiotics |
| NanoNebulant® | The biocide used in Nanosonics’ technological process |
| O&G | Obstetrics & Gynecology |
| OEM | Original Equipment Manufacturer. In the context of Nanosonics, OEMs are typically the manufacturers of ultrasound consoles and probes. |
| PCT | Patent Co-operation Treaty |
| Q1, 2, 3, or 4 | 3-monthly periods beginning 1 July, 1 October, 1 January and 1 April respectively |
| R&D | Research and Development |
| Reporting period | Year to 30 June |
| RoHS compliant | Restriction of Hazardous Substances |
| S+ | Sterilisation Plus, including prionicidal efficacy - Nanosonics new dimension of sterilisation based on the Company’s platform technologies |
| Sonex-HL | The biocide used in Nanosonics’ technological process |
| STI | Short Term Incentive |
| TEC | Total Employment Cost |
| TGA | Therapeutic Goods Administration – Australia |
| trophon® | The brand representing Nanosonics’ range of infection control solutions designed specifically for healthcare settings |
| trophon® EPR | The brand of Nanosonics’ device specifically designed to disinfect intracavity and surface ultrasound probes. |
Global Site
USA
Canada (English)
Canada (French)
French
Deutschland
UK
Australia
New Zealand
Japan
